Sánchez-Delgado Jordi, Calvet Xavier, Bujanda Luis, Gisbert Javier P, Titó Llúcia, Castro Manuel
Hospital de Sabadell, Institut Universitari Parc Taulí, Departament de Medicina, UAB, Barcelona, Spain.
Am J Gastroenterol. 2008 Sep;103(9):2220-3. doi: 10.1111/j.1572-0241.2008.01924.x. Epub 2008 Jun 28.
Cure rates of Helicobacter pylori infection with standard triple therapy are disappointingly low. A very effective, new sequential treatment schedule has recently been described. However, all studies published to date were performed in Italy; it is mandatory to confirm these results in other settings.
To assess the cure rate and the acceptability of a new sequential treatment regimen through a pilot study.
A hundred and thirty-nine patients (60% men, mean age 49.6 +/- 15.7 yr) were recruited from six centers. H. pylori status was assessed by histology, urease test or urea breath test. Sequential regime consisted of a 10-day treatment including a proton pump inhibitor (PPI) b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by a PPI b.d. clarithromycin 500 mg b.d. and metronidazole 500 mg b.d for the next 5 days. Eradication was determined 8 wk after the end of treatment by urea breath test or histology. Eradication rates were calculated both per protocol and by intention-to-treat.
Eradication was achieved in 117 out of 129 patients who returned for a follow-up test. The intention-to-treat eradication rate was thus 84.2% (95%CI: 77%-90%) and the per-protocol cure rate 90.7% (95%CI: 84%-95%). The treatment was well tolerated. Only 14 patients complained of mild side effects.
Sequential treatment seems highly effective for eradicating H. pylori.
标准三联疗法治疗幽门螺杆菌感染的治愈率低得令人失望。最近描述了一种非常有效的新序贯治疗方案。然而,迄今为止发表的所有研究均在意大利进行;必须在其他环境中证实这些结果。
通过一项初步研究评估一种新序贯治疗方案的治愈率和可接受性。
从六个中心招募了139名患者(60%为男性,平均年龄49.6±15.7岁)。通过组织学、尿素酶试验或尿素呼气试验评估幽门螺杆菌感染状况。序贯方案包括为期10天的治疗,前5天每天两次使用质子泵抑制剂(PPI)加1克阿莫西林,随后5天每天两次使用PPI、500毫克克拉霉素和500毫克甲硝唑。治疗结束8周后通过尿素呼气试验或组织学确定根除情况。按方案和意向性治疗计算根除率。
129名返回接受随访测试的患者中有117名实现了根除。意向性治疗根除率因此为84.2%(95%可信区间:77%-90%),按方案治愈率为90.7%(95%可信区间:84%-95%)。该治疗耐受性良好。只有14名患者抱怨有轻微副作用。
序贯治疗似乎对根除幽门螺杆菌非常有效。